Assessment of safety and tolerability of Herceptin subcutaneous administration in patients with HER2-positive early breast cancer: results of an open-label, randomized, multicenter, phase IIIB study

Authors :: A. Prokharau
E. Zhavrid
D. Kaidarova
S. Talayeva
N. Antonenkova
O. Shatkovskaya
Z. Rutzhanova
A. Manasheva
Source :: The Breast. 32:S27
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
medicine.medical_specialty
Tolerability
business.industry
Internal medicine
Medicine
Surgery
In patient
General Medicine
Open label
business
Early breast cancer

Full Text Access

Tools